Mother’s Day signifies so much to so many—celebration, gratitude, and yes, remembrance or loss. This year, we want to acknowledge just some of our many supporters who have taken their love for their moms and transformed it into a gift for our entire community. Whether biking across the country or putting on a virtual play, … Continued
Dr. Benoît Brangantini, of Mayo Clinic, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With his project, “Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM,” Dr. Bragantini aims to better understand how DNA damage and repair mechanisms can lead to ovarian cancer, and how these processes can be controlled to prevent ovarian … Continued
With spring finally upon us, we want to give a shout-out to a group of OCRA Heroes who welcomed the season by setting themselves into motion, both literally and figuratively, to raise awareness and funds for our shared cause. Movement was the main theme for all of these supporters, who helped keep the momentum going … Continued
Dr. Melanie Weigert, of University of Chicago, is a 2021 recipient of OCRA’s Mentored Investigator Grant. With her project, “Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA,” Dr. Weigert aims to identify biomarkers that can predict how cancer cells will respond to platinum-based treatments, helping guide patients with potentially platinum-resistant cancer toward alternative therapies. Dr. Weigert’s … Continued
Dr. Anne van Harten, of the Sidney Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer,” Dr. van Harten is designing and testing a new compound to target a … Continued
Dr. Sammy Ferri-Borgogno, of UT MD Anderson Cancer Center, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. With her project, “Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer,” Dr. Ferri-Borgogno is working to better understand ovarian cancer microenvironments, to find ways to better combat drug resistance. What initially sparked your … Continued
Dr. Arun Kanakkanthara, of Mayo Clinic, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With his project, “Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer,” Dr. Kanakkanthara is investigating ways to overcome tumor resistance to PARP inhibitors, a critical issue in ovarian cancer treatment. What initially sparked your interest in science? Science … Continued
Dr. Wei Zhou, of The Wistar Institute in Philadelphia, is a 2021 recipient of OCRA’s Ann & Sol Schreiber Mentored Investigator Award, mentored by Dr. Rugang Zhang. With his project, “Targeting the Mevalonate Pathway in ARID1A-Mutated Ovarian Cancer,” Dr. Zhou is investigating ARID1A mutations, in search of better therapeutic options for patients with ovarian clear … Continued
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” Dr. Ding is focusing on PARP inhibitors — some of the most effective drug therapies available for ovarian cancer, but that often come with a … Continued
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC,” explores DNA repair as a potential treatment avenue for clear cell ovarian carcinoma (CCOC). What initially sparked your interest in science? … Continued
In this time of giving thanks, we want to take a moment to look back and express our gratitude for the OCRA Heroes who stepped up for September’s Ovarian Cancer Awareness Month to sweat it out at Ovarian Fitness events around the country, all in the name of raising funds for critical research, advocacy and … Continued
April lives in Federal Way, Washington, and was diagnosed with Müllerian clear cell carcinoma. What has been your frustration in having a rare form of ovarian cancer? My biggest frustration is finding effective treatments and battling my insurance company to approve treatments. My insurance continues to deny treatments like immunotherapy, calling it investigational because there … Continued
Get email updates about research news, action alerts, and ways to join the fight.
